Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 14

Drug Profile

IC 14

Alternative Names: Anti-CD14 antibody

Latest Information Update: 19 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ICOS Corporation
  • Developer ICOS Corporation; Implicit Bioscience; University of Washington
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Monoclonal antibodies
  • Mechanism of Action CD14 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury
  • Phase I Motor neuron disease
  • Clinical Phase Unknown Adult respiratory distress syndrome
  • Discontinued Septic shock

Most Recent Events

  • 20 May 2020 Implicit Bioscience plans a phase II trial for Respiratory disease in USA (IV) (NCT04391309)
  • 15 May 2020 Implicit Bioscience and Massachusetts General Hospital plans the phase II HEALEY ALS Platform clinical trial for Amyotrophic lateral sclerosis in USA (PO) (NCT04390386)
  • 15 May 2020 Implicit Bioscience withdraws a phase II trial for Motor neuron disease and Amyotrophic lateral sclerosis in Australia (IV) due to lack of funding (NCT03508453)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top